(-0.29%) 5 057.01 points
(-0.81%) 38 150 points
(-0.46%) 15 641 points
(1.14%) $83.75
(-2.54%) $1.611
(0.28%) $2 345.00
(0.42%) $27.46
(1.12%) $926.05
(-0.31%) $0.932
(-0.25%) $10.96
(-0.46%) $0.799
(-0.06%) $92.27
Live Chart Being Loaded With Signals
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally...
Stats | |
---|---|
Today's Volume | 232 860 |
Average Volume | 1.42M |
Market Cap | 23.94M |
EPS | $0 ( 2024-02-28 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.25 |
ATR14 | $0 (0.00%) |
Immuron Ltd Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Immuron Ltd Financials
Annual | 2023 |
Revenue: | $1.80M |
Gross Profit: | $1.31M (72.54 %) |
EPS: | $-0.0166 |
Q2 | 2024 |
Revenue: | $2.36M |
Gross Profit: | $1.58M (67.09 %) |
EPS: | $-0.00910 |
Q4 | 2023 |
Revenue: | $1.22M |
Gross Profit: | $881 227 (72.17 %) |
EPS: | $-0.00790 |
Q3 | 2022 |
Revenue: | $610 530 |
Gross Profit: | $564 980 (92.54 %) |
EPS: | $-0.00400 |
Financial Reports:
No articles found.
Immuron Ltd
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III registration trial to reduce the risk of contracting travelers' diarrhea in the United States, and Phase II field trial for Travelers' Diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in Phase I/IIa clinical trial for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators